BIRC2 Expression Impairs Anti-Cancer Immunity and Immunotherapy Efficacy

Debangshu Samanta; Tina Huang; Rima Shah; Yongkang Yang; Fan Pan; Gregg L. Friedman

doi:10.1016/j.celrep.2020.108073

Related publications

Article2025

TAX1BP1-dependent autophagic degradation of STING1 impairs anti-tumor immunity

Ruoxi Zhang, Chunhua Yu, Herbert J. Zeh, Guido Guido Kroemer, Daniel J. Klionsky, Daolin Tang, Rui Kang

Letter2018

Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy

Jonathan Pol, Guido Guido Kroemer

Article2022

Roles of natural killer cells in immunity to cancer, and applications to immunotherapy

Natalie K. Wolf, Djem Kissiov, David H Raulet

Article2017

Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity

Shabnam Shalapour, Xue-Jia Lin, Ingmar N. Bastian, John Brain, Alastair D. Burt, Alexander A. Aksenov, Alison Vrbanac, Weihua Li, Andres Perkins, Takaji Matsutani, Zhenyu Zhong, Debanjan Dhar, José A. Navas-Molina, Jun Xu, Rohit Loomba, Michael Downes, Ruth T. Yu, Ronald M. Evans, Pieter C. Dorrestein, Rob Knight, Christopher Benner, Quentin M. Anstee, Michael Karin

Article2016

Neutrophil-Derived IL-1β Impairs the Efficacy of NF-κB Inhibitors against Lung Cancer

Allyson G. McLoed, Taylor P. Sherrill, Dong‐Sheng Cheng, Wei Han, Jamie A. Saxon, Linda A. Gleaves, Pingsheng Wu, Vasiliy V. Polosukhin, Michael Karin, Fiona E. Yull, Georgios T. Stathopoulos, Vassilis Georgoulias, Rinat Zaynagetdinov, Timothy S. Blackwell